Peer-influenced content. Sources you trust. No registration required. This is HCN.

GU Oncology NowGU Cancer: FDA Approves Product to Increase Access to PSMA PET Imaging for Prostate Cancer

Illucix is a preparation kit for gallium-68 PSMA-11 injection, an agent indicated for PET PSMA position tumors in patients with suspected prostate cancer metastasis who are eligible for initial definitive therapy and have suspected cancer recurrence based on elevated PSA levels.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form